Jounce Therapeutics Inc (JNCE) Gets a Sell Rating from J.P. Morgan

By Ryan Adsit

In a report issued on August 7, Cory Kasimov from J.P. Morgan maintained a Sell rating on Jounce Therapeutics Inc (JNCEResearch Report). The company’s shares closed on Friday at $4.20.

According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 2.9% and a 44.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.

Currently, the analyst consensus on Jounce Therapeutics Inc is a Hold with an average price target of $13.

See today’s analyst top recommended stocks >>

Based on Jounce Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.99 million. In comparison, last year the company had a GAAP net loss of $4.67 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.